Monday, June 7, 2021
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including JPMorgan Chase (JPM), PayPal Holdings (PYPL), and Thermo Fisher Scientific (TMO). These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
You can see all of today’s research reports here >>>
Shares of JPMorgan have outperformed the Zacks Major Regional Banks industry in the last one-year period (+51.4% vs. +47.2%). The Zacks analyst believes that branch openings in new regions, inorganic expansion strategies and strong mortgage banking business are expected to keep aiding financials in the upcoming quarters.
While the Fed's accommodative policy and near-zero rates are likely to hamper interest income and margins, a robust economic recovery will likely lead to rise in demand for loans. Furthermore, JPMorgan's impressive capital deployments reflect earnings strength and a solid balance sheet.
(You can read the full research report on JPMorgan here >>>)
PayPal shares have gained +21.2% over the last six months against the Zacks Internet Software industry’s loss of -11.7%. The Zacks analyst believes that PayPal is benefiting from robust growth in total payments volume owing to increasing net new active accounts.
Further, Venmo’s improving monetization efforts and rising adoption rate across various platforms are aiding the total active accounts growth. Additionally, solid momentum of core peer to peer and PayPal Checkout experiences is a tailwind. Also, accelerating transaction revenues are likely to continue driving revenues.
(You can read the full research report on PayPal here >>>)
Shares of Thermo Fisher have gained +2% in the past three months against the Zacks Medical Instruments industry’s gain of +2.5%. The Zacks analyst believes that with several takeovers including Advanced Bioprocessing buyout from BD and Patheon, Thermo Fisher is expanding inorganic growth profile.
In terms of end market, pharma and biotech registered growth on robust performance in bioproduction and pharma services. However, the pandemic has massively disrupted the global supply chain. Foreign currency fluctuations and a competitive landscape are other major downsides.
(You can read the full research report on Thermo Fisher here >>>)
Other noteworthy reports we are featuring today include PepsiCo (PEP), McDonald's (MCD) and Canadian National Railway Company (CNI).
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.
See these 7 breakthrough stocks now>>
Sheraz Mian
Director of Research
Note: Sheraz Mian heads the Zacks Equity Research department and is a well-regarded expert of aggregate earnings. He is frequently quoted in the print and electronic media and publishes the weekly Earnings Trends and Earnings Preview reports. If you want an email notification each time Sheraz publishes a new article, please click here>>>
Today's Must Read
New Branches, Strategic Buyouts to Aid JPMorgan (JPM) Growth
PayPal (PYPL) Benefits From Increasing Total Payment Volume
Thermo Fisher (TMO) Advances in Bioprocess, End Market Up
Featured Reports
Momentum in PepsiCo's (PEP) Snacking Business to Aid Growth
Per the Zacks analyst, PepsiCo's snacks/food business have been delivering solid sales over the past several quarters, on higher at-home consumption.
Robust Comps to Aid McDonald's (MCD), Traffic Woes Stay
Per the Zacks analyst, McDonald's various sales and digital efforts as well as positive comps likely to drive growth.
Dividends Aid Canadian National (CNI), Freight Revenues Hurt
The Zacks analyst is impressed with the company's efforts to reward its shareholders.
Vertex (VRTX) Cystic Fibrosis Drugs Up Sales, Pipeline Solid
Vertex has four cystic fibrosis (CF) drugs that generate strong product revenues. The Zacks analyst says its non-CF pipeline is also progressing rapidly with multiple data readouts expected in 2021.
TELUS (TU) Rides on Subscriber Additions Amid Competition
Per the Zacks analyst, TELUS is likely to gain from an accretive subscriber base in TELUS technology solutions and TELUS International, primarily driven by network investments and service offerings.
Cost-Control Focus Aids Expedia (EXPE) Amid Coronavirus Woes
Per the Zacks analyst, Expedia's cost-saving measures that include variable marketing and discretionary expenses cut to counter coronavirus-induced disruptions are positives.
Martin Marietta (MLM) Inorganic Drive Solid, Weather Woes Hurt
Per the Zacks analyst, Martin Marietta's focus on value-enhancing acquisitions is likely to strengthen its aggregates position.
New Upgrades
Expanding Clientele, Remote-Working Solutions Aids Zoom (ZM)
Per the Zacks analyst, Zoom is benefiting from solid adoption of remote working solutions and expanding subscribers base attributed to coronavirus-led distancing norms.
Growth Projects, Expansion Moves to Aid Agnico Eagle (AEM)
According to the Zacks analyst, Agnico Eagle will benefit from the progress of its major growth projects and its investment to expand mine efficiency and production.
Strategic Expansion & Focus on Digitalization Aid At Home (HOME)
Per the Zacks analyst, At Home is benefiting from solid expansion strategies in both existing and new markets in the United States. Also, the company's continuous focus on digitalization bodes well.
New Downgrades
Elevated Expenses Hurt Commerce Bancshares (CBSH) Profits
Per the Zacks analyst, increasing costs due to continued rise in salaries and employee benefits are likely to hurt Commerce Bancshares' bottom line. Exposure to risky loans also remains a concern.
Rising Expenses Impact Synovus' (SNV) Bottom-line Growth
Per the Zacks analyst, mounting expenses due to Synovus' investments in infrastructure and technology remains a major headwind.
Escalated SG&A Costs Hurt Helen of Troy's (HELE) Profits
Per the Zacks analyst, Helen of Troy is seeing higher SG&A costs. In fiscal fourth-quarter consolidated SG&A ratio rose 4.3 percentage points mainly due to greater marketing costs among others.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Thermo Fisher Scientific Inc. (TMO): Free Stock Analysis Report
PayPal Holdings, Inc. (PYPL): Free Stock Analysis Report
PepsiCo, Inc. (PEP): Free Stock Analysis Report
McDonalds Corporation (MCD): Free Stock Analysis Report
JPMorgan Chase & Co. (JPM): Free Stock Analysis Report
Canadian National Railway Company (CNI): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
